IP Library › Granted Patent US 11,497,801
Granted Patent B2
US 11,497,801 · App. 17/180,012 · Granted Nov 15, 2022

Compositions and methods of enhancing immune responses

Inventors: Sherryll Layton (Lisbon, NH); Jeffrey W. Hall (Minneapolis, MN)
A61K39/015A61K39/002A61K39/012A61K39/39A61P33/02A61K2039/523
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,497,801
App. No.
17/180,012
Granted
Nov 15, 2022
Kind
B2
Abstract

A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

Claims (14)

1. A vaccine vector comprising:

a polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

2. The vaccine vector of claim 1 wherein the vaccine vector is a bacterium.

3. The vaccine vector of claim 2 , wherein the bacterial vaccine vector is a Bacillus spp.

4. The vaccine vector of claim 1 further comprising one or more immunostimulatory polypeptides.

5. The vaccine vector of claim 1 wherein the antigenic polypeptide is present on the surface of the vaccine vector.

6. A pharmaceutical composition comprising the vaccine vector of claim 1 and a pharmaceutically acceptable carrier.

7. A vaccine vector comprising:

a polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

8. The vaccine vector of claim 7 wherein the vaccine vector is a bacterium.

9. The vaccine vector of claim 8 , wherein the bacterial vaccine vector is a Bacillus spp.

10. The vaccine vector of claim 7 further comprising one or more immunostimulatory polypeptides.

11. The vaccine vector of claim 7 wherein the antigenic polypeptide is present on the surface of the vaccine vector.

12. A pharmaceutical composition comprising the vaccine vector of claim 7 and a pharmaceutically acceptable carrier.

Continuity (1)
Related Publication 20220265802A1 · Aug 25, 2022